Intestinal microorganism marker related to non-small cell lung cancer prognosis immunity and nutrition state and application of intestinal microorganism marker
By identifying specific intestinal microbial markers and establishing relative abundance models, the inaccuracy of the evaluation of immune and nutritional status in patients with non-small cell lung cancer is solved, accurate prognosis evaluation and personalized medical treatment are achieved, and treatment effect and prognosis are improved. accuracy.
Patent Information
- Application Number
- CN202410971577.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-19
AI Technical Summary
The prior art is inaccurate, lags in evaluating the immune and nutritional status of patients with non-small cell lung cancer, and lacks effective intervention methods, resulting in inaccurate prognosis assessment.
By identifying and utilizing specific intestinal microbial markers, such as E. H. H., A.k.a., and Ruminococcus, a relative abundance model was established, and the Epsilon-Support Vector Regression model was used for evaluation, and detection reagents and systems were developed. , used to evaluate and improve the patient's immune and nutritional status.
Accurate assessment of the immune and nutritional status of patients with non-small cell lung cancer, provides personalized medical approaches, improves the accuracy of treatment strategies, and provides assistance in early identification of health risks, and improves the accuracy of postoperative prognosis assessment. .
Smart Images

Figure CN118932054A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an intestinal microbial marker related to the prognosis, immunity and nutritional status of non-small cell lung cancer and an application thereof. Background Art
[0002] The human intestinal flora and the host constitute an interconnected whole. Intestinal microorganisms can not only degrade and digest the nutrients in food, host vitamins and other nutrients, but also promote the differentiation and maturation of intestinal epithelial cells, thereby activating the intestinal immune system and regulating host energy storage and metabolism. These play an important role in human digestion and absorption, immune response, metabolic activity, etc.; therefore, the composition of intestinal microorganisms has an important impact on the individual's immune and nutritional status. The assessment of an individual's immune and nutritional status is crucial for health management, disease prevention, and improving disease prognosis. For example, the prognosis of patients with non-small cell lung cancer after surgery is closely related to their nutritional and immune status. However, the current immune and nutritional evaluation indicators are inaccurate, imprecise, and have a lag; nutritional indices such as PNI that evaluate disease prognosis involve clinical blood sampling, which is an invasive detection method, and there is a lack of effective and accurate intervention methods for improving immunity and nutrition. Therefore, a more effective, simple and interventionable method is needed to assess the individual's immune and nutritional status, so as to better evaluate the risks of affecting the immune system, metabolic health, nutrient absorption, and various chronic diseases. Summary of the invention
[0003] The purpose of the present invention is to provide an intestinal microbial marker related to the prognosis of non-small cell lung cancer immune and nutritional status and its application. By measuring the abundance of intestinal microbial markers, the immune and nutritional status of individuals can be better evaluated, which can play an important role in the treatment and health management of patients, thereby providing a new approach for personalized medicine and health management.
[0004] In the first aspect, the present invention provides an intestinal microbial marker related to the prognosis of non-small cell lung cancer, immune and nutritional status, using the following technical solution:
[0005] A gut microbial marker associated with the prognostic immune and nutritional status (PNI) of non-small cell lung cancer, wherein the gut microbial marker comprises: Eubacterium hallii, Akkermansia muciniphila, Ruminococcus callidus, Ruminococcus gnavus, Clostridium paraputrificum, and Haemophilus influenza.
[0006] The results of the present invention show that the intestinal abundance of Eubacterium hallii, Akkermansia and Ruminococcus siliquae in high PIN individual samples is significantly higher than that in low PIN individual samples; while the intestinal abundance of Ruminococcus siliquae in high PNI individual samples is significantly lower than that in low PNI individual samples. The abundance of Clostridium paraputrificum and Haemophilus influenza in low PNI patients tends to be higher than that in high PNI patients.
[0007] Preferably, the intestinal microbial markers for the prognosis of non-small cell lung cancer also include: Eubacterium ventriosum, Subdoligranulum, Coprococcus, OdoribacterN54MGS14, Ruminococcus A254MGS108, Actinobaculum oral taxon 183F0552, Lactobacillus brevis, and Haemophilus influenza.
[0008] The results of the present invention show that the samples of high PNI individuals are rich in Eubacterium convexum, Microsphaeria rare, Coprococcus, Odorobacterium, Ruminococcus and Actinobacillus; while the samples of low PNI individuals are rich in Lactobacillus brevis.
[0009] A gut microbial marker associated with prognostic immunity and nutritional status (PNI) of non-small cell lung cancer, wherein the gut microbial marker is divided into two intestinal types: Ruminococcus intestinal type and Bacteroids intestinal type in cluster analysis.
[0010] According to the experimental results of the present invention, high microbial diversity is enriched in samples of individuals with high immune and nutritional status (high PNI), while low microbial diversity is enriched in samples of individuals with low immune and nutritional status (low PNI).
[0011] According to the experimental results of the present invention, Ruminococcus enteric type Ruminococcus was enriched in samples of individuals with high immune and nutritional status (high PNI), while Bacteroids enteric type Bacteroids was enriched in samples of individuals with low immune and nutritional status (low PNI).
[0012] In the second aspect, the present invention provides an evaluation model for the prognosis immune and nutritional status of non-small cell lung cancer, which is characterized by the above-mentioned intestinal microbial markers, obtains the corresponding relationship between the relative abundance of the above-mentioned bacterial species and PNI, and standardizes the relative abundance data of the bacterial species. The input variable is the standardized relative abundance of the bacterial species, and the output variable is the PNI index. The Epsilon-Support Vector Regression model is used to establish a regression model between the relative abundance of the bacterial species and the PNI index.
[0013] In a third aspect, the present invention provides a reagent for detecting the above-mentioned non-small cell lung cancer prognosis microbial marker, the reagent comprising: a reagent for collecting a biological sample from a subject, a preparation for extracting microbial marker DNA, and a reagent for detecting microbial marker DNA and determining its abundance. The biological sample is human feces.
[0014] In a fourth aspect, the present invention provides a system for evaluating microbial markers for the prognosis of non-small cell lung cancer, wherein the system comprises the detection results of the intestinal microbial marker combination and an evaluation model.
[0015] The system further comprises a detection device.
[0016] The detection device includes a device for sequencing or detecting the abundance information of each intestinal microorganism in the intestinal microorganism combination.
[0017] In a fifth aspect, the present invention also provides a food and probiotics that assist in improving the prognosis of non-small cell lung cancer, immunity and nutritional status (PNI), and uses the corresponding food and probiotics to increase the abundance of bacteria that are positively correlated with nutritional immunity and reduce the abundance of bacteria that are negatively correlated with nutritional immunity.
[0018] Beneficial effects of the present invention:
[0019] 1) The present invention uses the relative abundance of intestinal flora and the patient's PNI index to establish the correlation between the diversity, enterotype and specific bacterial species of intestinal flora and PNI.
[0020] 2) The present invention uses the relative abundance of 6 specific species of intestinal flora and the patient's PNI index to construct a nutritional immunity assessment model. The model is applied to input the relative abundance information of 6 specific species of new individuals and output the results of nutritional immunity assessment. No invasive examination is required, and the test can be repeated many times. The nutritional immunity status of patients can be improved through the intervention of specific intestinal species. This provides a new way for personalized medicine and helps doctors develop more accurate treatment strategies.
[0021] 3) The present invention is not only applicable to patients with non-small cell lung cancer, but also to healthy people. By analyzing the relationship between microbial composition and immune and nutritional status, the invention helps to identify patients' health risks at an early stage. This enables medical professionals to take intervention measures before the disease worsens, improving the success rate of treatment.
[0022] 4) The application of the present invention helps to improve the accuracy and reliability of postoperative prognosis assessment and provide a reference for clinical treatment and management decisions. In stage I NSCLC patients, PNI is a strong predictor of overall survival, with an efficacy exceeding TNM. The research results of the present invention help to gain a deeper understanding of the relationship between intestinal microorganisms and immune and nutritional status. This helps to promote progress in the field of intestinal microbiology and pathophysiology research and provide a new scientific basis for future disease treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 , the result graphs of the prediction index of PNI for the prognosis of surgical treatment of patients with non-small cell lung cancer in Example 1, wherein, (A): the result graph of the retrospective evaluation of the PNI level of all clinical trial patients; (B): the result graph of the ROC curve constructed by the application of the logistic regression model to all clinical trial patients; (C): the result graph of the Youden index analysis of all clinical trial patients; (D): the result graph of the retrospective evaluation of the PNI level of clinical stage I patients; (E): the result graph of the ROC curve constructed by the application of the logistic regression model to clinical stage I patients; (F): the result graph of the Youden index analysis of clinical stage I patients.
[0024] Figure 2 , the result graph of the prediction index of PNI for the prognosis of surgical treatment of patients with non-small cell lung cancer in Example 1, wherein, (G): the result graph of PNI cutoff value analysis; (H): the result graph of multivariate analysis of clinical stage I patients; (I) the effect graph of PNI prognosis evaluation in patients at different clinical stages.
[0025] Figure 3 , the differences in intestinal microbial composition between the high PNI group and the low PNI group in Example 2; wherein, (A): Venn diagram of OTUs shared by the intestinal microbiota of patients with high and low PNI in non-small cell lung cancer; (B): α-diversity data diagram of the intestinal microbiota of patients; (C): PLS-DA analysis results of microbial community changes between groups.
[0026] Figure 4 , the difference in intestinal microbial composition between the high PNI group and the low PNI group in Example 2, wherein, (D): a graph showing the relative abundance of bacterial 16S rRNA sequences at the phylum level; (E): a graph showing the relative abundance of bacterial 16S rRNA sequences at the genus level;
[0027] Figure 5 , the differences in intestinal microbial composition between the high PNI group and the low PNI group in Example 2, wherein, (F): Cladogram analysis of the intestinal bacteria results of the high and low PNI patients with significant differences; (G): LEfSe analysis of the intestinal bacteria results of the high and low PNI patients with significant differences.
[0028] Figure 6 , specific intestinal types of the high PNI group and the low PNI group in Example 2; (A): Principal component analysis of the intestinal microbial composition of patients with non-small cell lung cancer divided the patients into two groups with good discrimination; (B): Relative abundance clustering determined the optimal cluster number Calinski-Harabasz (CH) Index, showing that the patients were divided into two categories; (C): Cluster analysis showed the relative abundance of Ruminococcus, Bacteroides and Prevotella at the genus level in the two clusters (Student's T test, *P<0.05, **P<0.01, ns: no significance); (D): The proportion of patients with high and low PNI in the two intestinal type clusters.
[0029] Figure 7 , qPCR relative abundance of 6 representative intestinal bacterial species in patients without PNI in Example 3. DETAILED DESCRIPTION
[0030] The embodiments of the present invention will be described in detail below in conjunction with the auxiliary figures and examples. Unless otherwise defined, the scientific and technological terms used herein are the meanings commonly understood by those of ordinary skill in the art of the present invention. The nomenclature and experimental methods used herein are well known and routinely used in the art. The operations performed using standard techniques are usually performed according to the product specifications and conventional technical requirements of the instrument consumables manufacturer and the reference materials provided herein.
[0031] Example 1 Determining the optimal cutoff value of PNI
[0032] To determine the optimal cutoff value of PNI in patients with non-small cell lung cancer (NSCLC), we first retrospectively evaluated the PNI levels of patients with different 5-year overall survival rates. Our analysis included a total of 289 postoperative patients. The PNI calculation formula was PNI = serum albumin (g / L) + 5 × absolute lymphocyte count (10 9 / L). Overall survival (OS) was defined as the time from surgery to death from NSCLC, and approximately 79.87% of patients survived for more than 5 years.
[0033] Figure 1The results in Figure A were a retrospective evaluation of the PNI levels of all patients with different 5-year overall survival rates. The analysis included a total of 289 postoperative patients. From the results, it can be seen that the average PNI value of all patients was 48.80±4.20, ranging from a minimum of 40.00 to a maximum of 66.90; patients who survived for 5 years had significantly higher PNI levels (49.40±4.12) compared with deceased patients (46.40±3.64) (P<0.05). In order to further study whether there is a change in the PNI cutoff value in clinical stage I patients, Figure 1 In D, the PNI levels of 154 clinical stage I patients with different 5-year overall survival rates were retrospectively evaluated; the scatter plot shows the calculation of the PNI of surviving patients and the PNI of deceased patients based on the 5-year survival of 154 clinical stage I patients after surgery. From the results, it can be seen that among clinical stage I patients, the PNI level of patients who survived for 5 years was significantly higher.
[0034] Figure 1 In Figure B, a logistic regression model was used to construct the ROC curve. Based on the 5-year survival results of all patients, the adjusted PNI ROC curve showed an AUC of 0.6261 (P = 0.0004). Figure 1 A logistic regression model was used to construct the ROC curve in E. Based on the 5-year survival results of patients in clinical stage I, the adjusted PNI ROC curve showed an AUC of 0.7099 (P=0.0003).
[0035] Figure 1 Youden index analysis of all patients in Figure 3 revealed a PNI cutoff value of 46.2; the prognostic performance of PNI showed sensitivity (81.08%) and specificity (46.15%). Figure 1 Analysis of the Youden index for patients in clinical stage I revealed that the PNI cutoff value was 46.22; the prognostic performance of PNI showed sensitivity (79.67%) and specificity (64.52%). These findings suggest that a PNI cutoff value of 46.2 is effective for patients at all clinical stages, especially for those in stage I, in whom it showed higher specificity than patients at all stages.
[0036] Figure 2 In the study, 154 patients in clinical stage I were divided into two groups according to the cutoff value of PNI 46.2: high PNI group (PNI ≥ 46.2, n = 109) and low PNI group (PNI < 46.2, n = 45). The Cox multivariate regression model evaluated the diagnostic performance of PNI as a prognostic indicator, and the results showed that the overall survival rate of patients with high PNI values was significantly better than that of patients with low PNI values in all clinical stages. Figure 2Further multivariate analysis showed that the prognostic evaluation efficiency of PNI in patients with clinical stage I was higher than that of TNM stage. Figure 2 The results showed that PNI showed good prognostic evaluation effect in patients with clinical stage I and II. However, PNI did not show good prognostic effect in postoperative NSCLC patients with clinical stage III.
[0037] Taken together, these results suggest that PNI, as an indicator of the nutritional and immune status of patients, may be a valuable tool for predicting the prognostic outcome of patients with early-stage postoperative NSCLC.
[0038] Example 2 Differences in intestinal microbial composition between high PNI group and low PNI group of non-small cell lung cancer patients
[0039] In compliance with relevant ethical requirements, stool samples from 14 HPNI patients with non-small cell lung cancer and 14 LPNI patients with non-small cell lung cancer were obtained. All specimens were from the Second Xiangya Hospital of Central South University. After obtaining the two groups of fresh stool specimens to be tested, the stool in the middle part was immediately scooped out with a sterile cotton swab in the clean bench, placed in a sterile cryotube, and immediately frozen in liquid nitrogen and stored in a -80℃ refrigerator. The total microbial DNA in the stool samples was extracted using the HiPure Stool DNA Kits (D3141-02) from Magen according to the instructions and stored at -20℃ for later use. In order to detect the quality of the extracted total microbial DNA, the DNA concentration and OD260 / 280 and OD 260 / 230 values were determined using Nanodrop, and 1% agarose gel was prepared, 500ng DNA was spotted, and the gel was run at 100V in the DNA electrophoresis tank for 20min, and the DNA was observed under blue light for degradation. The extracted DNA samples were sequenced using the Illumina Miseq / Novaseq 6000 sequencing platform of Beijing Aovison Gene Technology Co., Ltd., and the sequencing strategy was PE250 / PE300.
[0040] The data of intestinal microbial composition were mapped to the reference genome by 16S rRNA sequencing to generate an evolutionary tree file, and the sequencing data were split and divided into different samples according to the barcode sequence by QIIME software. The sequencing data were then filtered and spliced using Pear software. After splicing, the sequences less than 270bp were removed using Vsearch software, and the chimera sequences were removed using the uchime method according to the Gold Database database to retain high-quality microbial sequence reads. The upparse algorithm of Vsearch (v2.7.1) software was then used to perform OTU clustering (classify the sequenced sequences (Cluster), and divide the sequences into groups according to their similarity, and one group is an OTU) on the high-quality sequences, with a sequence similarity threshold of 97%. The OTU representative sequence was compared with the Silva138 database using the BLAST algorithm, and the e-value threshold was set to 1e-5 to obtain the species classification information corresponding to each OTU, and the species information of the community was annotated at each level (kingdom, phylum, class, order, family, genus). Finally, the R package (RDP classifier) was used to analyze and compare the species diversity of the two groups of samples, and finally the bacteria with significant differences in the two groups of samples were screened and identified.
[0041] In this analysis step, 16S rRNA sequencing analysis used multiple indicators such as Chao1, observed species, PD_whole_tree and Shannon index to evaluate the α diversity of the samples and associate them with immune nutritional status. The results can be seen Figure 3 Medium~5.
[0042] The Venn diagram of OTUs shared by the gut microbiota between high and low PNI in NSCLC patients is shown in Figure 3 Middle A Figure 3 In B, four indicators including Chao1, observed species, PD whole tree and Shannon index were used to evaluate the α diversity of the patient's intestinal microbiota. The results showed that the intestinal microbial diversity of patients with high PNI was significantly higher than that of patients with low PNI. Figure 3 Figure C uses PLS-DA (partial least squares discriminant analysis) to examine the overall differences in intestinal microorganisms between patients with high and low PNI. The results show changes in microbial communities between PLS-DA analysis groups, indicating that there are significant differences in the composition of intestinal microorganisms between patients with high and low PNI. Figure 4 D and E show the relative abundance of bacterial 16S rRNA sequences at the phylum and genus levels, respectively. Figure 5In F and G, Cladogram (phylogenetic tree kinship classification method) and LEfSe (linear discriminant analysis effect size) were used to analyze the intestinal microorganisms of patients with high and low PNI, respectively. The results showed that the intestinal bacteria of patients with high and low PNI analyzed by Cladogram and LEfSe were significantly different. LEfSe analysis was used to screen out the species of intestinal microorganisms with differences between patients with PNI higher than 46.2 and lower than 46.2. The results are shown in the figure. Figure 5 As shown in G, the results showed that the microbial composition of the high immune and nutritional status groups was rich in Akkermansia, Eubacterium halli, Eubacterium coprostanoligenes, Eubacteriumventriosum, Subdoligranulum, Coprococcus, Clostidium methylpentosum DSM5476, OdoribacterN54MGS14, Ruminococcaceae bacterium GD1, Ruminococcus Callidus, Ruminococcus N15MGS57, Ruminococcus A254 MGS108, Eubacterium Coprostanoligenes, Actinobaculum oral taxon 183F0552, NK4A214, Eubacterium Ventriosum, Rikenellaceae, Alistipes, Adlercreutzia, Sellimonas, Eggerthellaceae, and UCG. 002, Oscillospiraceae, Ruminococcus, Verrucomicrobiae, Verrucomicrobiota; the intestinal microbial composition of the low immune and nutritional status groups was rich in Ruminococcus gnavus, Clostridium paraputrifucum, Lactobacillus brevis, Haemophilus influenzae, Haemophilus, Haemophilusinfluenzae, Pasteurellaceae, Pasteurellales, Tyzzerella sp Marseille P3062.
[0043] The two groups of samples selected above are clustered by using the Partitioning Around the Center (PAM) algorithm based on the Jensen-Shannon distance between samples, and the optimal number of clusters is determined by the Calinski-Harabasz (CH) index. The calculation results are visualized by PCoA, as shown in the figure. Figure 6 Middle: Principal component analysis (PCA) revealed that lung cancer patients could be classified into 2 distinct clusters, each corresponding to a unique enterotype: Bacteroids (enterotype 1) and Ruminococcus (enterotype 3) (see Figure 6 A clustering algorithm based on the relative abundance of each genus was used to determine the optimal number of clusters, represented by the Calinski-Harabasz (CH) index 2 (see Figure 6 The main contributors to each enterotype were identified and Figure 6 As shown in C. Figure 6 As shown in middle D, patients with high PNI were mainly associated with the Ruminococcus enterotype, while patients with low PNI were mainly associated with the Bacteroids enterotype.
[0044] Example 3
[0045] According to the results in Example 2, 6 bacteria with specific primers at the species level were selected for qPCR verification. According to the representative bacterial species with different expression in high PNI and low PNI in Example 2, 6 representative bacterial species were selected: the bacterial species with significantly higher intestinal abundance in high PNI patients than in low PNI patients: Eubacterium hallii, Akkermansia muciniphila, Ruminococcus callidus; the bacterial species with significantly higher intestinal abundance in low PNI patients than in high PNI patients: Ruminococcus gnavus. The abundance of Clostridium paraputrificum and Haemophilus influenza in low PNI patients tended to increase compared with high PNI patients.
[0046] First, find the 16S rDNA gene sequence of the differential strains in the NCBI database, and design primers for the variable region of bacterial 16SrDNA. See Table 1 for details. The designed primers use the TestPrime tool (https: / / www.arb-silva.de) to check the bacterial coverage of the primers. The lower the coverage, the higher the specificity of the primers. Finally, the primers with the lowest coverage are selected for synthesis. In this example, in addition to the differential strain primers, we set a pair of reference primers to amplify the universal sequence of microorganisms (Maeda H, et al. Quantitative real-time PCR using TaqMan and SYBR Green for Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, tetQ gene and total bacteria. FEMS Immunology & Medical Microbiology. 2003, 39: 81-86). Experimental method and steps for qPCR detection of relative abundance of differential microorganisms in fecal samples: First, the optimal annealing temperature of primers for each bacterial species was determined by gradient annealing temperature PCR; then, the DNA extracted from each sample was used as a template, and qPCR was performed with specific primers for each differential bacterial species, and the number of cycles (Ct value) of the corresponding primers for each bacterial species was recorded; finally, the relative abundance of each differential bacterial species in each sample was calculated, and the relative abundance (Relative abundance, Ra) of any bacterial species i can be expressed as: Ra(i) = (1 / 2)^(Cti-Ctc), where Cti represents the number of cycles of bacterial species i, and Ctc represents the number of cycles of universal primers. A total of 20 μL. The qPCR reaction conditions were: 1) incubation at 50℃ for 2 minutes; 2) pre-denaturation at 95℃ for 2 minutes; 3) denaturation at 95℃ for 15 seconds, annealing at 56℃ for 15 seconds, and extension at 72℃ for 1 minute, and repeated for 40 cycles; 4) melting curve analysis, default program.
[0047] Table 1
[0048]
[0049] The representative bacterial species with differential expression were detected by fluorescent quantitative PCR, and statistical analysis was performed by T test. P less than 0.05 was considered statistically significant. The analysis results showed that at the bacterial species level, the intestinal abundance of Eubacterium hallii, Akkermansia muciniphila, and Ruminococcus callidus in patients with high PNI was significantly higher than that in patients with low PNI ( Figure 7 ), while the intestinal abundance of Ruminococcus gnavus in patients with high PNI was significantly lower than that in patients with low PNI. These significantly different bacterial species can be used as potential microbial markers for evaluating the prognosis and survival of patients with early non-small cell lung cancer ( Figure 7 ). However, the abundance of Clostridium paraputrificum and Haemophilus influenza in patients with low PNI tended to be higher than that in patients with high PNI ( Figure 7 ).
[0050] Epsilon-Support Vector Regression was used to establish a regression model between the relative abundance of the above six bacterial species and PNI, and training predictions were performed in two independent cohorts of patients with non-small cell lung cancer and respectively. First, this model standardized the relative abundance of the six bacterial species in the cohort and recorded the mean and standard deviation of each bacterial species. On this basis, the relative abundance of the corresponding bacterial species in the cohort was standardized to . On the standardized data, this model uses the Gaussian kernel-based support vector regression model Epsilon-Support Vector Regression, in which the prediction function is defined as follows:
[0051] Where is the predicted PNI index, is the vector composed of the relative values of the strains in the training sample, is the Lagrange multiplier of the support vector, and is the Gaussian kernel function. During the training process, the optimization goal of this Epsilon-Support Vector Regression model is:
[0052]
[0053] Where f(x i ) is the predicted PNI index, x i is a vector composed of the relative values of bacterial species in the training sample, a i and is the Lagrange multiplier of the support vector, K(x, x i) is the Gaussian kernel function. During the training process, the optimization goal of this Epsilon-SupportVector Regression model is:
[0054]
[0055] At the same time, the following constraints are met:
[0056]
[0057] Among them, is the control boundary hyperparameter, is the slack variable, and C represents the regularization parameter. The non-small cell lung cancer patient cohort and the parameter C = 10 were used for training and prediction, where the mean absolute error (MAE) of PNI predicted by training was 2.048, and the mean absolute error (MAE) of PNI predicted by training was 2.918.
[0058] From the above results, it can be concluded that the model performance was evaluated on two independent cohorts of non-small cell lung cancer patients, and the mean absolute error (MAE) of the trained and predicted PNI was obtained, indicating that the model can effectively predict the PNI index based on the relative abundance of 6 microorganisms. Applying this model, the PNI index can be obtained by inputting the qPCR relative abundance values of the 6 bacteria.
[0059] In order to verify the actual application effect of the model, two patients with high and low PNI indexes were selected, the PNI values of the two patients were calculated according to the method of Example 1, and then the prediction was performed according to the method of Example 3. The specific steps are as follows:
[0060] We train our SVM model using the PCR and PNI data in the training set;
[0061] Input the data of the independent test set into the trained model and predict the PNI value of the test set. The test results are as follows:
[0062] Low PNI group: the true PNI value is 45.85, and the predicted PNI value is 45.59; high PNI group: the true PNI value is 52.85, and the predicted PNI value is 52.35; the true PNI value is calculated and tested by the method in Example 1, and the predicted PNI value is tested by the method and model of the present invention. These results show that the PNI values tested by our method and the method in Example 1 are very close, indicating that the method of the present invention can accurately predict the PNI value of patients with non-small cell lung cancer.
Claims
1. An intestinal microbial marker related to the prognosis of non-small cell lung cancer, immune and nutritional status, characterized in that: The intestinal microbial markers specifically include: Eubacterium hallii, Akkermansia, Ruminococcus spp., Ruminococcus spp., Clostridium parasporabilis, and Haemophilus influenzae.
2. The intestinal microbial marker according to claim 1, characterized in that: The intestinal microbial markers also include: Eubacterium convexum, Micrococcus rare, Coprococcus, Odorbacterium, Ruminococcus, Actinobacillus, Lactobacillus brevis, and Haemophilus influenzae.
3. A model for evaluating the prognosis of non-small cell lung cancer immune and nutritional status, characterized in that: According to the intestinal microbial marker according to claim 1 or 2, the corresponding relationship between the relative abundance of the bacterial species and the PNI is obtained, the relative abundance data of the bacterial species are standardized, the input variable is the standardized relative abundance of the bacterial species, the output variable is the PNI index, and the Epsilon-Support Vector Regression model is used to establish a regression model between the relative abundance of the bacterial species and the PNI index.
4. A reagent for detecting microbial markers for the prognosis of non-small cell lung cancer according to any one of claims 1 to 2, the reagent comprising: a reagent for collecting a stool sample from a subject, a preparation for extracting microbial marker DNA, and a reagent for detecting microbial marker DNA and determining its abundance.
5. A system for evaluating microbial markers of prognosis, immune and nutritional status of non-small cell lung cancer, characterized in that: The system comprises the detection result of the intestinal microbial marker combination according to any one of claims 1 to 2 and the evaluation model according to claim 3.
6. The system for evaluating the prognosis of non-small cell lung cancer with microbial markers of immune and nutritional status according to claim 5, characterized in that: The system also includes a detection device.
7. The system for evaluating the prognosis of non-small cell lung cancer with microbial markers of immune and nutritional status according to claim 6, characterized in that: The detection device includes a device for sequencing or detecting the abundance information of each intestinal microorganism in the intestinal microorganism combination.
8. A food and probiotics for improving the prognosis of non-small cell lung cancer, immunity and nutritional status, characterized in that: The corresponding food and probiotics are used to increase the abundance of any bacterial species positively correlated with nutritional immunity in claims 1 to 2, and reduce the abundance of any bacterial species negatively correlated with nutritional immunity in claims 1 to 2.
Citation Information
Patent Citations
Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and / or tyrosine kinase inhibitors and markers of responsiveness to such treatments
US20220370514A1
Gut Microbiome as a Predictive Biomarker of Outcomes for Chimeric Antigen Receptor T-Cell Therapy
US20240084403A1
A predictive score of cancer immunotherapy outcome based on ecological analysis of gut microbiota
WO2024094817A1
